Navigation Links
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
Date:1/28/2008

SAN DIEGO, Jan. 28 /PRNewswire/ -- Cylene Pharmaceuticals has appointed Dr. Kenna Anderes to its management team. Dr. Anderes, who brings 17 years of life sciences research experience with a focus on cancer biology research, will serve as Vice President of Cancer Biology. With Cylene's most advanced compound, quarfloxin (CX-3543), now in Phase II development, Dr. Anderes will be leading Cylene's biology and pre-clinical research teams to advance other targeted small molecule oncology compounds into the clinic during 2008.

"I am excited about the opportunity to advance more of Cylene's novel drug candidates into the clinic," said Dr. Anderes. "These compounds are orally available and have the potential to become effective and convenient therapeutics for cancers that currently lack effective, patient-friendly treatments."

Dr. Anderes joined Cylene from Pfizer, Inc., where she had led large project teams in oncology and cancer biology research over the past twelve years. Prior to her tenure at Pfizer, Dr. Anderes held several group leader and senior scientist positions at major biotechnology and pharmaceutical companies, such as Warner Lambert and Agouron.

"Dr. Anderes has the ideal background and experience to accelerate and expand our product pipeline," said Dr. William G. Rice, Cylene's President and Chief Executive Officer. "Her expertise in cancer biomarkers and imaging, as well as her leadership experience in pharmaceutical research, will enable her to make meaningful contributions to our management team."

Dr. Anderes earned a Ph.D. in pharmacology from the Southern Illinois University School of Medicine, and she performed a postdoctoral research fellowship in pharmacology at the University of California San Diego.

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a private company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening can
'/>"/>

SOURCE Cylene Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
3. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
6. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
7. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
8. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
9. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
10. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... involve a range of resource and environmental problems. ... resin and a clever recycling strategy, Uppsala researchers ... alternative. Their study will be presented soon in ... think our discovery can open several doors to ... the future, says Daniel Brandell, Associate Professor at ...
(Date:9/29/2014)... , September 29, 2014 ... research report "Epigenetics Market by Product (Modifying Enzymes, ... Kit, Bisulphite Conversion Kit, Reagents), by Research ... - Global Forecast to 2019", published by ... major drivers, restraints, opportunities, current market trends, ...
(Date:9/29/2014)... 29, 2014 ACEA Biosciences, Inc. ... the 2014 iCELLigence Research Grant for his proposal ... instrument is an impedance based real-time label-free cellular ... Department of Biomedical Engineering at Yale University currently ... projects in Professor Rong Fan's laboratory ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... and The Channel Group ("TCG"), a leader in ... advisors, have formed an alliance to expand the ... prospective clients. With the alliance, Burnham Securities will ... the scientific, clinical medicine and management in healthcare ...
Breaking Biology Technology:Smart, eco-friendly new battery to solve problems 2Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... Development and InnovationMOUNTAIN VIEW, Calif., April 22 ... Pharmaceuticals & Biotechnology group assesses a variety of ... in cancer treatment. Physicians, nurses and patients ... reconstitution, home vs. office administration parameters, and barriers ...
... 22 GeneGo, Inc., a leading provider of software ... , today announced that the University of Cardiff has ... researchers will have access to GeneGo,s MetaCore, training and ... their partner relationship with GeneGo to provide a pathway ...
Cached Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:9/29/2014)... In order to support the world,s needs to ... and more, new and more efficient catalytic materials ... researchers, including several from Wayne State University, is ... new grant from the National Science Foundation. , ... of Multicomponent Materials for Electrocatalytic Cascade Reactions," was ...
(Date:9/29/2014)... five-year, $6 million grant for clinical research and ... of safe and effective treatments for cocaine addiction. ... Institutes of Health, National Institute on Drug Abuse, ... for Cocaine Use Disorder to oversee preclinical and ... moving forward with more expensive large-scale clinical trials. ...
(Date:9/29/2014)... A review article published online in Behavioral ... happen in the brain as a result of chronic ... sleep cycle. , Clinical assessments and research indicate ... severely disrupted sleep. This can occur when people are ... when they are abstaining. , "Sleep-wake disturbances can ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... EMBO announced today the selection of 23 young ... network of 315 current and past Young Investigators. ... years of age who have established their first laboratories ... in ten European countries, Israel and Singapore. The success ...
... the University of Sheffield,s Faculty of Engineering, have shown ... turning it into glass reduces its volume by 85-95 ... plutonium, creating a stable end product. The approach ... wastes generated during the eventual clean-up of the damaged ...
... to find the necessities of life. It,s a complex task, ... environment to navigate the safest and fastest routes to food ... certain important events, such as finding a meal, will occur. ... fundamental behaviors, navigation and the anticipation of a reward, had ...
Cached Biology News:Volume of nuclear waste could be reduced by 90 percent, says new research 2Anticipation and navigation: Do your legs know what your tongue is doing? 2Anticipation and navigation: Do your legs know what your tongue is doing? 3Anticipation and navigation: Do your legs know what your tongue is doing? 4
FGF Receptor 1 Antibody...
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Biology Products: